Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T02:19:49.776Z Has data issue: false hasContentIssue false
  • English
  • Français

Clostridioides difficile toxin testing and positivity in Manitoba, Canada

Published online by Cambridge University Press:  19 June 2020

Christiaan H. Righolt Open the ORCID record for Christiaan H. Righolt [Opens in a new window] ,
Geng Zhang ,
Gregory W. Hammond ,
Philippe Lagace-Wiens  and
Salaheddin M. Mahmud Open the ORCID record for Salaheddin M. Mahmud [Opens in a new window]
Christiaan H. Righolt
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Geng Zhang
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
Gregory W. Hammond
Affiliation:
Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Philippe Lagace-Wiens
Affiliation:
Shared Health, Clinical Microbiology, Saint-Boniface Hospital, Winnipeg, Manitoba, Canada
Salaheddin M. Mahmud*
Affiliation:
Vaccine and Drug Evaluation Centre, Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
*
Author for correspondence: Salaheddin Mahmud, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

We assessed Clostridioides difficile toxin testing and positivity for all patients in Manitoba hospitals during June 2016–November 2018. The testing rate was 30 per 10,000 patient bed days (95% confidence interval [CI], 30–31) and the incidence rate was 3.5 per 10,000 patient bed days (95% CI, 3.3–3.7). The context of testing is essential to the interpretation of data among jurisdictions.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 41 , Issue 10 , October 2020 , pp. 1212 - 1214
Check for updates
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lambert, PJ, Dyck, M, Thompson, LH, Hammond, GW.Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, using interim surveillance definitions. Infect Control Hosp Epidemiol 2009;30:945–951.10.1086/605719CrossRefGoogle ScholarPubMed
Freeman, J, Bauer, MP, Baines, SD, et al.The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529–549.10.1128/CMR.00082-09CrossRefGoogle ScholarPubMed
Lessa, FC, Gould, CV, McDonald, LC.Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55:S65–S70.10.1093/cid/cis319CrossRefGoogle ScholarPubMed
Leffler, DA, Lamont, JT.Clostridium difficile infection. N Engl J Med 2015;372:1539–1548.10.1056/NEJMra1403772CrossRefGoogle ScholarPubMed
Dubberke, ER, Carling, P, Carrico, R, et al.Strategies to prevent Clostridium difficile infections in acute-care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:S48–S65.10.1017/S0899823X00193857CrossRefGoogle ScholarPubMed
Davies, K, Davis, G, Barbut, F, Eckert, C, Petrosillo, N, Wilcox, M.Longitudinal European Clostridium difficile Infection Diagnosis Surveillance Study (LuCID) shows effects of place, patient age and testing method on CDI reporting. Open Forum Infect Dis 2015;2. doi: 10.1093/ofid/ofv131.57.Google Scholar
Davies, K, Davis, G, Barbut, F, Eckert, C, Petrosillo, N, Wilcox, MH.Variability in testing policies and impact on reported Clostridium difficile infection rates: results from the pilot Longitudinal European Clostridium difficile Infection Diagnosis surveillance study (LuCID). Eur J Clin Microbiol Infect Dis 2016;35:1949–1956.10.1007/s10096-016-2746-1CrossRefGoogle Scholar
Wilkinson, K, Gravel, D, Taylor, G, et al.Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions. Am J Infect Control 2011;39:177–182.10.1016/j.ajic.2011.01.007CrossRefGoogle ScholarPubMed
Canadian Institute for Health Information. Inpatient Hospitalizations: Volumes, Length of Stay, and Standardized Rates. Ottawa: Canadian Institute for Health Information; 2019.Google Scholar
Katz, KC, Golding, GR, Choi, KB, et al.The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009–2015). Canad Med Assoc J 2018;190:E758–E765.CrossRefGoogle Scholar
Canadian Nosocomial Infection Surveillance Program. Summary Report of Healthcare Associated Infection (HAI), Antimicrobial Resistance (AMR) and Antimicrobial Use (AMU) Surveillance Data from January 1, 2013 to December 31, 2017. Ottawa: Public Health Canada; 2018.Google Scholar
Planche, TD, Davies, KA, Coen, PG, et al.Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013;13:936–945.10.1016/S1473-3099(13)70200-7CrossRefGoogle ScholarPubMed
Miller, MA, Hyland, M, Ofner-Agostini, M, Gourdeau, M, Ishak, M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile–associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137–140.CrossRefGoogle ScholarPubMed
Polage, CR, Gyorke, CE, Kennedy, MA, et al.Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:1792–1801.10.1001/jamainternmed.2015.4114CrossRefGoogle ScholarPubMed
Ashraf, Z, Rahmati, E, Bender, JM, Nanda, N, She, RC.GDH and toxin immunoassay for the diagnosis of Clostridioides (Clostridium) difficile infection is not a ‘one size fits all’ screening test. Diagn Microbiol Infect Dis 2019;94:109–112.10.1016/j.diagmicrobio.2018.12.010CrossRefGoogle Scholar
Singh, H, Nugent, Z, Yu, BN, Lix, LM, Targownik, LE, Bernstein, CN.Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology 2017;153:430–438.e432.10.1053/j.gastro.2017.04.044CrossRefGoogle ScholarPubMed
Lessa, FC, Mu, Y, Bamberg, WM, et al.Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–834.CrossRefGoogle ScholarPubMed